Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Bicycle Therapeutics plc BCYC

Healthcare Biotechnology
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BCYC)

Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline

Business Wire February 3, 2026

Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

Business Wire January 12, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Shareholders to Inquire about Securities Investigation

ACCESS Newswire January 2, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Connect

ACCESS Newswire January 1, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Reach Out

ACCESS Newswire December 31, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Shareholders to Learn More About the Investigation

ACCESS Newswire December 30, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation

ACCESS Newswire December 29, 2025

Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

ACCESS Newswire December 28, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC

ACCESS Newswire December 28, 2025
View More News ››

Opinion & Analysis (NDAQ:BCYC)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BCYC)

Be the first to post on this bullboard.

Mullen Group Ltd

Mullen Group Ltd

Mullen Group Ltd. provides a range of trucking and logistics services in Canada and the United States. It operates through ...
View More »

Podcasts